| :: transition therapeutics |
AIM Therapeutics Advances Asthma Therapeutics Program AIM Therapeutics Inc. NeuroMedix was acquired by Transition Therapeutics in March 2007.
Transition Therapeutics Inc. (Nasdaq: TTHI) reports that the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug
menafn: Transition Therapeutics AnnouncesDepartureIts PresidentChief Financial OfficerTORONTO, Dec 9, 2011 (GlobeNewswire via
Transition Therapeutics inc.†. Diane Paul,; Philémon Rakoto. Article first published online: 21 JAN 2010. DOI: 10.1506/ap.7.2.6. 2008 Canadian Academic
Q2 EPS C$1.05 vs est C$0.02 loss/share * Q2 rev at C$29.7 mln vs C$987828 year ago * U.S.-listed shares up 7 pct after market (Recasts,
Elan Corporation, plc and Transition Therapeutics, Inc. notified clinical investigators of modifications to the Phase II study AD201 and open
27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq: ) announced that Phase 2
Transition Therapeutics (TTHI) and Elan (ELN) Modify ELND005 Development Transition Therapeutics shrinks yearly loss to 19.3M; revenue up 79 per cent
Says TT-223 fails to show efficacy in study * Says other licensing deal with Eli Lilly stays Sept 17 (Reuters) - Transition Therapeutics Inc (TTH.
Results 1 - 20 of 105 TRANSITION THERAPEUTICS INC.: TTHI (Nasdaq Global
Transition Therapeutics Inc. (TTHI, TTH.T) agreed to sell 3.7 million shares in a private placement at a 16% discount to Friday's close to raise
Transition Therapeutics would like to help people suffering from disease to make the transition to good health. The biotechnology firm is working on therapies to
Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease 15.12.2009 | Nachricht
Get detailed financial information on Transition Therapeutics Inc. (TSE:TTH) including real-time stock quotes, historical charts & financial news, all for free!
Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada.
TORONTO, Nov. 22, 2011 -- Transition Therapeutics Inc. today announced the closing of its previously disclosed | November 23, 2011.
Read about how life science organizations have benefited from doing business in Toronto.
TORONTO, Dec. 1, 2011 -- Transition Therapeutics Inc. , a product-focused biopharmaceutical company developing therapeutics for disease
TORONTO, Sep 19, 2011 (GlobeNewswire via COMTEX) --Transition Therapeutics Inc. (Transition or the Company) /quotes/zigman/39571
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company, developing therapeutics for disease indications with large markets.
Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol )
TORONTO, CANADA -- June 12, 2006 -- Transition Therapeutics Inc. announced that Nature Medicine, one of the world's leading peer reviewed medical
Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX: TTH) announced today the first patient has been dosed in a
Global Market Direct's pharmaceuticals report, Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 provides data on the Transition
Transition Therapeutics Inc. announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223.
Transition Therapeutics (NASDAQ:TTHI) is a development stage biopharmaceutical based in Toronto, Canada. This is a very small company
Message Boards: TTHI (Transition Therapeutics). Tweet This · chart · TTHI ( Transition Therapeutics - Msgs, Twts, Profile). Last: 1.30 -0.02 (-1.52%) · Vol: 19832
DUBLIN & TORONTO -- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ:TTHI) today announced the
Transition Therapeutics (NASDAQ:TTHI) is lowest with an EV/EBITDA ratio of 0.76. Transition Therapeutics Inc. is a biopharmaceutical
Transition Therapeutics Inc, Premium Company Profile: , published April 2008, pages 46, IntroductionTransition Therapeutics is a biopharmaceutical company,
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement. Lilly to Acquire Exclusive Rights to Gastrin Based
Transition Therapeutics Inc. (TTHI) Thursday reported a net loss of C$2.9 million or C$0.12 per share, narrower than the loss of C$3.5 million or
Transition Therapeutics Acquires Certain Assets of Forbes Medi-Tech (Research)
TRANSITION THERAPEUTICS INC (TTH:CN) stock price & investing information. Find TRANSITION THERAPEUTICS INC historical stock quotes, key
Get Transition Therapeutics Inc. business contacts for
Transition Therapeutics Announces US Million Private Placement.
By Christopher P. Singer Transition Therapeutics, Inc. announced in an April 3, 2007 press release that its investigational Alzheimer's disease
Presentations at 2009 Alzheimer s Association International Conference on Alzheimer s Disease Support Ongoing Phase 2 Trial Jul 13, 2009 - Elan Corporation
Transition Therapeutics is focused on the research and development of products primarily for the treatment of central nervous system (CNS) and metabolic
Business Editors & Health/Medical Writers BIOWIRE2K TORONTO--(BUSINESS WIRE)--Nov. 28, | Article from Business Wire November 28,
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman. Matthew R.
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics. Inc. (TSX: TTH, NASDAQ:TTHI) today announced the United States
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
Transition Therapeutics (TTHI) stock quote, charts, historical data, financials.
Get detailed financial information on Transition Therapeutics Inc (NASDAQ:TTHI) including real-time stock quotes, historical charts & financial news, all for free!
View the latest TTHI - Transition Therapeutics real-time stock quote information. Get detailed breaking investment performances, chart analysis, stock prices,
Elan and Transition Therapeutics inked an exclusive, worldwide collaboration agreement for the joint development and commercialization of a
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep
Transition Therapeutics reaches a turning point Nearly ten years after launching Transition Therapeutics, veteran entrepreneur and scientist
Transition Therapeutics Inc. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and
Hoovers company profile of Transition Therapeutics Inc.. Find detailed business information such as key executives, financials and other corporate data on
2011-12-31 TTHI: Transition Therapeutics Inc Institutional Investments! Transition Therapeutics Inc dumped -74633 shares, change of -100% to total position of
Transition Therapeutics (USA) Inc. company research & investing information. Find executives and the latest company news.
On January 17, 2002, Transition Therapeutics Inc. (CDNX: TTH) and Waratah Pharmaceuticals Inc. (CDNX: WAR) completed their merger. The businesses and
TORONTO, Sep 19, 2011 (GlobeNewswire via COMTEX News Network) -- Transition Therapeutics Inc. ("Transition" or the "Company")
Transition Therapeutics Inc. 101 College Street Suite 220,
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and Transition Therapeutics Inc.
Transition Therapeutics announces that Mr. Elie Farah, the company's President and Chief Financial Officer, has left the Company to pursue new challenges.
Company profile for Transition Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by
Transition Therapeutics Toronto (TSX): TTH. Regenerative therapy for diabetes and small-molecule drug against Alzheimer's disease
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced the achievement of the
Stock market news and stock research. Financial news, stock news and stock makrket update about the stocks, ETF and mutual funds listed on the NYSE, AMEX
Credit & Investment Research, Thomson StreetEvents: TRANSITION THERAPEUTICS INC Q4 2010 Earnings Conference Call Transcript
Get the latest TTHI - Transition Therapeutics Inc. earnings, stock market performance data and financial news.
Stock analysis for TTHI:US. Get stock price, historical stock charts & news for Transition Therapeutics Inc, in the Therapeutics industry.
Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH.TO) ( Nasdaq:TTHI), a product-focused biopharmaceutical company
DUBLIN, Ireland & TORONTO -- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced
Transition Therapeutics Inc company profile in Toronto, Canada. Our company profile report for Transition Therapeutics Inc includes business information such
Transition Therapeutics Sells 3.7M At 16% In Private Deal. Subscriber RehabCare Group, Transition Therapeutics: Biggest Price Gainers (RHB, TTHI). Feb 8
Transition Therapeutics Inc., a biopharmaceutical company, has reported that net loss and comprehensive loss for the first quarter ended
TORONTO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ( Transition) (TSX:TTH) today announces the appointment of Ms.
27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced that Phase
Elan and Transition Therapeutics also ran into trouble with ELN-0005, their partnered anti-aggregation agent. The top two doses (1000mg and 2000mg BID)
Transition Therapeutics Inc. (NASDAQ: TTHI) today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of
Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes. TORONTO, Sept. 12 /CNW/ - Transition
TORONTO, March 3, 2010 -- Transition Therapeutics Inc. today announced that it has acquired the rights to a series of preclinical compounds
Global Markets Direct :: Transition Therapeutics Inc. Product Pipeline Review H2 2011 :: September 2011 :: Pharmaceutical market research report.
Elan paid Transition Therapeutics $9 million in January 2011 and is In August 2010, Elan and Transition Therapeutics had reported data on
On February 26, 2004, Transition Therapeutics announced that it had finished an extended phase 1 clinical trial of therapy with I.N.T. in people with type 1
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company, developing therapeutics for disease indications with
Transition Therapeutics Inc. 415 Yonge Street Suite 1103. Toronto Ontario M5B2E7 Canada Phone: 416-260-7770 Fax: 416-260-2886. SEARCH JOBS
Highlights include Patheon raising $280 million from its note placement, Verio Therapeutics getting phagocytosed by Fate (but remaining in Ottawa) and Lorus
Transition Therapeutics Inc. ( Transition or the Company ) (TSX TTH) (Nasdaq TTHI) announced that Phase 2 clinical study data of ELND005 in
featured press releases, both from Transition Therapeutics Inc. and Review of current pipeline of Transition Therapeutics Inc. human therapeutic division.
5 /PRNewswire/ - Transition Therapeutics Inc. (CDNX: TTH) announced today that it has acquired the intellectual property to Biogenesys' methlydonor
M of Transition Therapeutics Inc (TTHI) stock bought by Jack Schuler.
Transition Therapeutics Inc.: News Release [February 22, 2011 - 08:10 AM PST]: Feb. 22, 2011 (GlobeNewswire) -- TORONTO, Feb. 22, 2011
TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (
Transition Therapeutics Announces US$5 Million Private Placement. TORONTO 21, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics
TORONTO, Sep 17, 2010 -- Transition Therapeutics Inc. /quotes/comstock/15*!tthi /quotes/nls/tthi /quotes/comstock/11t!e:tth announced today
The Transition Therapeutics Inc. (TTHI) Competitors by Product report shows Transition Therapeutics Inc. products and services according to the actual sector or
Find financial news for Transition Therapeutics Inc. (NYSEAMEX:TTHI) using Google Finance.
Sponsor: Transition Therapeutics. Information provided by: Transition Therapeutics. ClinicalTrials.gov Identifier: NCT01357421
EV/EBITDA ratio of Transition Therapeutics (CA8937162094 - TTH) and its peer group for financial analysis.
Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization,
21, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced that it
9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX: TTH) (Nasdaq:TTHI) today announces that Mr. Elie Farah, the
View Transition Therapeutics Ord TTHI investment & stock information. Get the latest Transition Therapeutics Ord TTHI detailed stock quotes, stock data,
No Hype - No Ads Just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, Montreal, Nasdaq, NYSE, Amex,
TORONTO, Dec 9, 2011 (GlobeNewswire via COMTEX) -- Transition Therapeutics Inc. ("Transition") /quotes/zigman/39571 CA:TTH -15.38%
22, 2011 -- Transition Therapeutics Inc. today announced the closing of its previously disclosed private placement financing issuing.
Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq: TTHI) today announced the closing of its previously disclosed
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST.
{Globe Newswire via BioPortfolio} TORONTO, Sept. 27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the
Transition Therapeutics, Inc. Address: Toronto, Ontario, CA
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with
Transition Therapeutics Inc. has announced the appointment of Nicole Rusaw- George as its CFO.
Transition Therapeutics, Inc. ( NASDAQ: TTHI ) ( TSX: TTH ); Transition Therapeutics, Inc. Home. Partner : Elan Corporation. ELND005 (AZD-103) for Alzheimer's
Transition Therapeutics Inc., a biopharmaceutical company, has announced that the first patient has been dosed in a Phase I clinical study of
SC 13G/A - Transition Therapeutics Inc - On 2/8/11 - EX-99.1 - Statement of Beneficial Ownership - Seq. 2 - Joint Filing Agreement - Accession
Forum overview for "TTHI: Message Board for TRANSITION THERAPEUTICS INC " forum on InvestorVillage: Stock Message Boards
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of 12, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics Inc.
Transition Therapeutics IncTSX/Alpha:TTHview on NASDAQ » · Help. Symbol Lookup. No Matches were found for. Additional matches for Go. We've made
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and discussing Transition Therapeutics Inc. Stocks.
Transition Therapeutics Licenses Diabetes Regenerative Therapy to Novo Nordisk A/S.
Results 1 - 17 of 17 SC 13G/A, TRANSITION THERAPEUTICS INC. (FEINBERG LARRY N), 12/08/11. SC 13G/A, TRANSITION THERAPEUTICS INC. (FMR LLC)
Transition Therapeutics Inc. ("Transition") (TSX:TTH) today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial
Business Editors & Health/Medical Writers BIOWIRE2K TORONTO--(BUSINESS WIRE)--Nov. 27, | Article from Business Wire November 27, 2002.
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401. TORONTO, Dec 12, 2011
The Transition Therapeutics Inc. (TTHI) Company Profile report lists of key business relationships for Transition Therapeutics Inc. are all
New Market Report: Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011.
Review and download historical prices and charts for Transition Therapeutics Inc. (NYSEAMEX:TTHI).
27/04/2006 - Transition Therapeutics Receives Clearance to Initiate Phase I Clinical Trial with Alzheimer's Disease Product AZD-103. Attention Business Editors
Our research team will bring you any news or updates about Transition Therapeutics Inc. as they come into the public realm in the coming
Transition Therapeutics Inc. company profile,Transition Therapeutics Inc. Address:101 College St., Ste. 220 TorontoON M5G 1L7 Canada,Website:, Contact
TRANSITION THERAPEUTICS. January 27, 2004. Clinical-stage biotech with potential breakthrough therapy for diabetes. All values in C$ unless otherwise
Transition Therapeutics gets $9.45mm in private investments on Strategic Transactions, Feb-01-2006.
Transition Therapeutics Announces First Quarter Fiscal 2008 developing therapeutics for disease indications with large markets, today
Results 1 - 7 of 10 Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Transition Therapeutics Appoints New Chief Financial Officer
Transition Therapeutics completes private placement. print; bookmark; archives Transition Therapeutics Inc. (TSX:TTH. 4 words displayed of
View the basic TTH.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare TRANSITION THERAPEUTICS INC. against other
12, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX: TTH) today announces the appointment of Ms. Nicole
TORONTO, Sep 27, 2011 (GlobeNewswire via COMTEX News Network) -- Transition T.
Transition Therapeutics (Transition) is a Canadian based biopharmaceutical company, engaged in developing novel therapeutics for disease
Versant Partners has downgraded Transition Therapeutics (TSX:TTH; NASDAQ: TTHI) to “neutral” from “buy” and slashed its price target to $3.25 from $6.25,
Transition Therapeutics Inc.(Nasdaq: TTHI) today announced that it has entered into agreements to issue 3703703 common shares at a price of
Financial News - Transition Therapeutics, Inc. (TTHI.O) - Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2010
Transition Therapeutics - (Canada) Ordinary Shares Stock Quote, News, Stock Chart, SEC Filings NASDAQ Stock Market TTHI.
Transition Therapeutics Inc. 220-101 College St Toronto, ON M5G 1L7 Tel: (416) 260-7770. Toll-free: (877) 311-5272. Fax: (416) 260-2886. Contact Name
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401 - Dec 12, 2011. © 2011 Transition Therapeutics
Transition Therapeutics Inc. ("Transition") to acquire all of the outstanding shares of NeuroMedix. "This deal with Transition represents good value for our
Transition Therapeutics Commences Phase I Human Trial For I.N.T(TM) Dr. Tony Cruz, Chairman and CEO of Transition, said that the
DUBLIN & TORONTO --(BUSINESS WIRE)--Apr. 23, 2009-- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH,
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2011 Financial Results on Tuesday, May 10th, at 4:30 P.M. EDT
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Transition Therapeutics Announces the Departure of Its President and Chief
Transition Therapeutics to Trade on NASDAQ Capital Market.
Since acquiring Protana in November 2005, Transition Therapeutics has been using the company s Optimol technology to identify small
Stock quote for Transition Therapeutics, Inc. (TTHI) - Get real-time last sale and extended hours stock prices, company news, charts, and
Transition Therapeutics Inc. said Friday its potential type 2 diabetes drug failed in a clinical trial and the company will end development.
Free Online Library: Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease. by
Take a look at TTHI if you are looking for a stock with deep meaning to it.
Transition Therapeutics Announces Positive Data from E1-I.N.T." Clinical Trials in JDRF Partners With Transition Therapeutics Inc. to Develop a Beta Cell
Elan Pays Transition $9M in Amended Deal for Phase II Alzheimer Candidate · Transition Therapeutics and Lilly Expand Diabetes Partnership through
Transition Therapeutics Inc. stock price today: (TTHI) stock quote, price history, earnings per share, technical analysis chart and breaking news.
Transition Therapeutics has a Market Cap of 33.44M. Transition Therapeutics Market Cap (TTHI) charts, historical data, comparisons and more.
TRANSITION THERAPEUTICS INC.(TTHI)SEC FILINGS. View all filings and insider trading for TRANSITION THERAPEUTICS INC..
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced that the first patient has been
Company profile for Transition Therapeutics Inc. in Toronto,ON. Get accurate business information including key contacts, company financials and more in the
22, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced the
Transition Therapeutics, Inc. is a biopharmaceutical company that develops novel Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and discussing Transition
Transition Therapeutics Inc. (NYSEAMEX:TTHI) is a product-focused biopharmaceutical company developing therapeutics for disease
Zacks Analyst Blog Highlights: Elan, Transition Therapeutics, Pfizer, Novartis AG, Johnson & Johnson and Forest Laboratories-Zacks Analyst
Transition Therapeutics Inc. Announces Initiation Of Phase 1 Clinical Study Of Transition Therapeutics Inc. announced that the first patient has been dosed in
DUBLIN, Dec 15, 2009 (BUSINESS WIRE) -- Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Transition Therapeutics Announces the Departure
Transition Therapeutics Inc. (Transition Therapeutics) is a publicly held biopharmaceutical company. The company is engaged in the drug development program
Transition Therapeutics Provides Update on Diabetes Program.
7, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the " Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused
September 27th, 2011 - Transition Therapeutics Inc. ("Transition" or the " Company") (TSX: TTH, NASDAQ:TTHI) announced that Phase 2
Transition Therapeutics Announces Third Quarter Fiscal 2010 Financial Results TORONTO -- Transition Therapeutics Inc. , a product-focused
Transition Therapeutics Completes US$5 Million Private Placement.
TORONTO, April 3 /CNW/ - Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that the United States Food and Drug
Free article about 'Elan Pharmaceuticals pays Transition Therapeutics Inc $9 M in amended deal for Phase II alzheimer.
A good President's Day for Transition Therapeutics (TTHI). On Monday the company posted an unexpected profit for the second quarter,
Transition Therapeutics Inc. announced a series of actions to strengthen the Company's drug discovery group. Transition has acquired certain
Get the latest index performance and chart outlook for TRANSITION THERAPEUTICS INC. (TTH.TO).
Company profile, information and contact info for Transition Therapeutics Inc. - 101 College Street, Suite 220, Toronto, ON from ProFile Canada, Canada's most
Free Business profile for TRANSITION THERAPEUTICS INC at 101 COLLEGE TRANSITION THERAPEUTICS INC specializes in: Medicinal Chemicals and
Transition Therapeutics (TSE:TTH) (NASDAQ:TTHI) said Tuesday that positive phase-two clinical study data for its small molecule drug
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2011 Financial Results on Monday, February 7th, at 4:30 P.M. EST
Transition Therapeutics Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a
Anti-diabetes compounds. ALZHEIMER'S DISEASE TYPE 2 DIABETES /
Results 1 - 10 of 38 Assignee(s): TRANSITION THERAPEUTICS INC | Inventor(s): CRUZ TONY + 1. TRANSITION THERAPEUTICS INC View patent details for
Transition Therapeutics Announces US$5 Million Private Placement.
Transition Therapeutics USA Inc is located at 11099 N Torrey Pines Rd Ste 230 La Jolla, CA. Phone: 858-626-2930. . Post a message and leave a review for
Transition Therapeutics (TTHI) is up after it said late Monday it earned C$1.05 per share in Q2, better than the Thomson Reuters mean for a loss of C$0.02.
menafn: Transition Therapeutics Appoints New Chief Financial OfficerTORONTO, Dec 12, 2011 (GlobeNewswire via COMTEX) --Transition
Report Cites Planned ELND005 Phase 3 in Alzheimer's, TT401/TT402 Dual GLP- 1 Agonists for Type 2 Diabetes and TT301/302 for
Through its Industry Discovery and Development Partnership Program, JDRF is providing Transition Therapeutics funding over two years for
Finance: TORONTO -- Transition Therapeutics Inc. ("Transition") today announces that Mr. Elie Farah, the Company's President and Chief
Latest Transition Therapeutics Share Price and News. Transition Therapeutics has an emerging pipeline of preclinical drug candidates acquired externally and
TORONTO, August 30, 2007 PRNewswire-FirstCall - Transition Therapeutics Inc. ( Transition ) announced today the completion of Phase I
Q1 2012 Earnings Call - Transition Therapeutics, Inc., - Call Street Report.
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
Transition Therapeutics Inc. (TTHI) shares were up almost 5% Friday morning as investors react positively to an announced collaboration with
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary
Goliath's Transition Therapeutics Inc. Company Profile provides detailed company information on Transition Therapeutics Inc. located in
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary Global Market Direct's pharmaceuticals report,
Transition Therapeutics Inc. (TTHI) - Financial and Strategic Analysis Review - new company profile and swot report published Transition
Transition Therapeutics Inc. financial and business news, updates, and information from The New York Times and other leading providers.
Canada's Transition Therapeutics says that it has acquired the rights to a series of preclinical compounds from US drug major Eli Lilly in the
Symbol: tthi, Name: Transition Therapeutics Inc., Title: Transition Therapeutics Inc . (TTHI) Stock Quote.
Transition Therapeutics Inc. Announces First Quarter Fiscal 2003 Financial Results from Business Wire.
Transition Therapeutics (TTHI) is up after it said late Monday it earned C$1.05 per share in Q2, better than the Thomson Reuters mean for a
Latest Transition Therapeutics Share Price and News. A biopharmaceutical company developing novel therapeutics.
New York and Toronto listed biopharmaceutical company Transition Therapeutics (TSX:TTH, NASDAQ:TTHI) has expanded the number of
Just because a drug has managed to successfully meet earlier trial goals, it's no guarantee it will continue to do so. On Tuesday, Gilead, Elan
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011, Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary Global Market
TORONTO, March 21 - - Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that it has signed an agreement to offer to purchase all of the
Transition Therapeutics (Nasdaq: TTHI) today announced that it has entered into agreements to issue 3703703 common shares at a price of
28 /PRNewswire-FirstCall/ -- Transition Therapeutics Inc. ("Transition" or the " Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce
Transition Therapeutics (through its acquisition of Waratah Pharmaceuticals), in collaboration with Novo Nordisk, is developing E1-INT, an injectable islet
Transition therapeutics confident of deal with Novo on diabetes treatment. World Heart shuffles top two executives.
US:TTHI - Get Stock quote detail for Transition Therapeutics Inc. Stock quotes include the latest US:TTHI market price and fundamental investing data,
Transition Therapeutics Completes US$5 Million Priv.
Transition Therapeutics Inc. (Transition Therapeutics) is Canada based health care biopharmaceutical company. The organization is involved in the medicine
Transition Therapeutics Appoints New Chief Financial Officer.
Transition Therapeutics (Nasdaq:TTHI) has been downgraded by TheStreet Ratings from from a hold to sell..
Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX: TTH) will hold a conference call on Thursday, December 1,
Transition Therapeutics reported it will halt development of an experimental type 2 diabetes drug, TT-223, being developed with Eli Lilly after a
Transition Therapeutics Receives Anniversary Payment from Stem Cell To date , Transition has received $800000 in cash payments and is
Free Online Library: Transition Therapeutics Enhances Intellectual Property Portfolio For Its Multiple Sclerosis Program. by "PR Newswire";
TORONTO, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ( Transition) (TSX:TTH) (Nasdaq:TTHI) today announces that Mr.
Transition Therapeutics Inc. (NASDAQ:TTHI). + Watch TTHI. on My Watchlist. $1.47 0.02 (+1.64%). 1/5/2012 3:33 PM
Transition Therapeutics Inc. (TTHI), On Jan 10: 1.49 0.00 (0.00%) Please send us feedback. Message Boards Settings Transition Therapeutics Inc.
The directory is an ongoing effort by CanBiotech to profile all North American, U.K., German, France, Netherlands, Indian, Taiwan and other emerging biotech
Transition Therapeutics Inc. - Product Pipeline Review - H2 2011 Transition Therapeutics Inc. - Product Pipeline Review - H2 2011 Summary
Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations. TORONTO, June 18 /CNW/ - Transition Therapeutics
Transition Therapeutics (TTHI) Promotes Nicole Rusaw-George to CFO Dec Transition Therapeutics announces initiation of TT-401 Phase l
Transition Therapeutics. transitiontherapeuticslogo www.transitiontherapeutics. com. Get More From MaRS, MaRS NEWSLETTERS. Facebook Twitter Vimeo
Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study
3/3/2010-Transition Therapeutics (NASDAQ:TTHI) said early Wednesday that it has acquired the rights to a series of diabetes-related
Transition Therapeutics Inc. (Symbol:TTH) SWOT Analysis, Strategy, Revenues and Profits, This report is systematically updated by our analysts for each new
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Transition Therapeutics Announces Executive
20, 2002 Transition Therapeutics Inc. ("Transition") (TSX VENTURE:TTH) today announced that it has commenced a Phase I human trial of its
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST
Get free quotes, charts & company news on Transition Therapeutics.
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to bePresented at the International Conference of Alzheimer's
Transition Therapeutics' detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma
Collection of recommend articles and news on Transition Therapeutics Inc, including etc. The latest articles such as: Transition Therapeutics
Transition Therapeutics is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets.
Transition Therapeutics Inc. (TTH) - Financial and Strategic SWOT Analysis Review, published August 2011, pages 25, Transition Therapeutics Inc. ( Transition
Transition Therapeutics Inc. - Product Pipeline Review, H2 2011: , published September 2011, pages 54, Transition Therapeutics Inc. - Product Pipeline Review
LifeSci Advisors Announces Investment Opinion on Transition Therapeutics, Inc. Transition Therapeutics shrinks yearly loss to 19.3M; revenue up 79 per cent
NeuroMedix receives acquisition offer by Transition Therapeutics. TORONTO, Ontario - March 21, 2007: NeuroMedix Inc. ("NeuroMedix")
Transition Therapeutics, Inc. (NASDAQ:TTHI) Hear what millions of investors are saying now about Transition Therapeutics, Inc. with
Dr. Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since
Results 1 - 21 Reports the approval received by Transition Therapeutics Inc. to conduct the first phase of trials of its islet neogenesis therapy in Great Britain.
Transition Therapeutics Inc. (NASDAQ: TTHI) is seeing shares surge in after- hours activity. It has signed a pact with Eli Lilly and Co. (NYSE:
Transition Therapeutics has a R&D Expense of 2.19M. Transition Therapeutics R&D Expense (TTHI) charts, historical data, comparisons and
Ellipsis makes deal with Transition Therapeutics on Strategic Transactions, Nov- 01-2004.
Transition Therapeutics Inc. is a Canadian biopharmaceutical company developing novel approaches and therapeutics to inhibit inflammatory and fibrotic
INFO) - June 5, 2007 - Transition Therapeutics Inc. (TSX: TTH) announced today that it has filed a Registration Statement on Form 40-F
Preview and download documents about transition therapeutics
T.TTH Transition Therapeutics Inc. Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results 12/1/2011 4:01:28 PM - GlobeNewswire
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Lilly and Transition Therapeutics Announce
Transition Therapeutics Inc. is a publicly traded biopharmaceutical company developing novel approaches and therapeutics for the treatment of diabetes,
TORONTO, Nov. 5 /PRNewswire-FirstCall/ -- Transition Therapeutics Inc. (" Transition" or the | Article from PR Newswire November 5, 2007.
Up to date news for the parmaceutical and biotechnology industries.
Up to date analysis of Transition Therapeutics, Inc. (TTHI) and its stock by hedge fund managers and industry experts. Find out what Transition Therapeutics, Inc.
Elan and Transition Therapeutics Inc. Announce Global Collaboration to Develop and Commercialize Alzheimer's Disease Drug AZD-103 from
Deal builds on existing collaboration focused on Transition's clinical-stage gastrin-based drugs.
Collection of recommend articles and news on Transition Therapeutics, including etc. The latest articles such as: Transition Therapeutics Inc.
9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the " Company") (TSX:TTH) (Nasdaq:TTHI) announced today that
Global Markets Direct :: Transition Therapeutics Inc. ? Product Pipeline Review ? Q1 2011 :: June 2011 :: Pharmaceutical market research report.
Transition Therapeutics Inc. tth go to snapshot add to favorites. post. see all posts , Overall Quality 2+, Overall Quality 3+, Overall Quality 4+, Overall Quality 5
Name: